These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy. Arslan B; Onuk Ö; Hazar İ; Aydın M; Çilesiz NC; Eroglu A; Nuhoglu B Tumori; 2017 Mar; 103(2):204-208. PubMed ID: 27470607 [TBL] [Abstract][Full Text] [Related]
23. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy]. Heidenreich A; Ohlmann C; Ozgür E; Engelmann U Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521 [TBL] [Abstract][Full Text] [Related]
24. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441 [TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968 [TBL] [Abstract][Full Text] [Related]
27. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings. Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763 [TBL] [Abstract][Full Text] [Related]
28. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026 [TBL] [Abstract][Full Text] [Related]
29. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
30. Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. Oh JJ; Hong SK; Lee S; Sohn SJ; Lee SE Int Urol Nephrol; 2013 Feb; 45(1):121-7. PubMed ID: 23054323 [TBL] [Abstract][Full Text] [Related]
31. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827 [TBL] [Abstract][Full Text] [Related]
32. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656 [TBL] [Abstract][Full Text] [Related]
33. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003 [TBL] [Abstract][Full Text] [Related]
34. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients. Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy. Miyake H; Muramaki M; Furukawa J; Tanaka H; Inoue TA; Fujisawa M Urol Oncol; 2013 Nov; 31(8):1511-6. PubMed ID: 22658882 [TBL] [Abstract][Full Text] [Related]
36. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945 [TBL] [Abstract][Full Text] [Related]
37. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213 [TBL] [Abstract][Full Text] [Related]
38. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features. Bauman TM; Ewald JA; Huang W; Ricke WA BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327 [TBL] [Abstract][Full Text] [Related]
39. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964 [TBL] [Abstract][Full Text] [Related]